The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / October / What's Next for Prenatal Screening?
Omics Liquid biopsy Screening and monitoring Molecular Pathology

What's Next for Prenatal Screening?

Review highlights gaps in understanding of fetal DNA in maternal blood that may be limiting prenatal testing

10/16/2026 News 3 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Topic Commentary

Share

Objective:

Review how the biology of cell-free fetal DNA (cffDNA) may limit noninvasive prenatal testing (NIPT) and identify research directions that could improve it.

Approach:
  • Review focus: The review examines cffDNA’s origins, structure, and transport in maternal blood, and considers how these features affect NIPT.
  • Research priorities: The authors call for studies to establish cffDNA’s cellular origin and determine how much circulating DNA is associated with extracellular particles.
Key Findings:
  • cffDNA is a small fraction of circulating DNA, is difficult to distinguish from maternal DNA, and may not always represent the fetal genotype.
  • Much of the DNA called “fetal” originates from the placenta; placental mosaicism can make its genotype differ from the fetus.
  • Circulating cffDNA includes fragments of varied sizes and forms, including circular DNA, ultrashort fragments, and fragments longer than 500 base pairs.
  • The mechanism by which cffDNA circulates remains unresolved; direct evidence for release in apoptotic extracellular vesicles is lacking.
  • The article reports that 47% of high-risk NIPT results are false alarms and require confirmation through invasive diagnostic testing.
Interpretation:

The authors suggest that better understanding of cffDNA biology could enable fetal-DNA enrichment using features such as fragment size, density, molecular associations, or placental surface markers. They note that the biology must be better defined before NIPT can reliably progress from screening to comprehensive genetic diagnosis.

Limitations:
  • The review describes unresolved questions about cffDNA’s cellular origin, circulation, and relationship to fetal genotype.
  • The context does not provide details of the review’s methods or evidence-selection process.
Conclusion:

The authors identify immunoaffinity enrichment and microfluidics, alongside sequencing and bioinformatics advances, as potential approaches for improving NIPT after the underlying biology is clarified.

Sources:
  • Article context; review published in Science Advances

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.